December 27, 2021

Phapros Secures Sales Growth in The Third Quarter of 2021 Through Reinforcing Innovations and Marketing Strategies

Jakarta, 27 Desember 2021 – PT Phapros Tbk, one of the national pharmaceutical companies in Indonesia, acquired a net sales growth of 9.5 percent compared to the same period in the previous year as reflected in its audited financial statements for the third quarter of 2021.

The sales growth was supported by the performance of the Ethical Branded segment. The sales revenue in Ethical Branded segment alone experienced significant growth of up to 66 percent compared to the same period in the previous year.

In the third quarter of 2021, Phapros also recorded an operating profit growth of 2.6 percent compared to the same period in 2020.

President Director of Phapros, Hadi Kardoko, said that the significant growth in the ethical drug segment was triggered by the increasing number of people seeking treatment in hospitals for non-Covid cases.

"The pharmaceutical industry is categorized as a moderately raised industry during the Covid-19 pandemic, which is marked by the increasing demand for vitamins and drugs related to Covid-19, but experiencing a decline in demand in the non-covid drug segment. With the increasing performance of the Ethical Branded drug segment, which is mainly used through doctor's prescriptions at clinics or hospitals, this indicates that now people are willing to undergo non-covid treatment in hospitals, which may have been delayed during the pandemic," said the director.

He added that since the pandemic hit in mid-2020, the board of directors have taken various measures which are considered agile, adaptive and innovative.

On the other hand, the company also makes research and development innovation a step forward to encourage sustainable company growth. Towards the end of 2021, Phapros has just launched its new product, Cardismo extended release (Cardismo XR), which is a medicine for heart and cardiovascular diseases.

Hadi Kardoko said that one of his considerations in developing the product was because the number of people with heart and cardiovascular disease in Indonesia is still quite high and has the potential to increase in the future, where at least 15 out of 1,000 people or 4.2 million people suffer from the cardiovascular disease, and 2,784,064 of them suffer from heart disease.

Hadi explained that Cardismo XR, which is made from the active ingredient called Isosorbide mononitrate, is a development of the previous Cardismo Phapros product. The difference is that this product is a slow-release or extended-release (XR) tablet. With previous Cardismo, patients with coronary heart disease had to take medication 2 - 3 times a day, now with Cardismo XR, patients only need to take 1 time a day with effects that can be felt throughout the day, so patient comfort and compliance for taking the medicine are guaranteed.

"Phapros is optimistic that the performance and double digit growth in the next 3 years will be generated by this innovative new product," he added.